SAN DIEGO, Calif. — Artis BioSolutions said it has entered into a definitive agreement to acquire Syngoi Technologies, a Spanish biotechnology company focused on enzymatic approaches to manufacturing synthetic DNA, as it expands its platform for advanced-therapy development and manufacturing.
The acquisition is expected to strengthen Artis’s strategy of accelerating gene-to-drug discovery across multiple therapeutic modalities by adding faster and more cost-effective enzymatic-based synthetic DNA manufacturing capabilities.
Following the closing of the transaction, Artis plans to establish a U.S. operating presence for Syngoi’s technology through its wholly owned subsidiary, Landmark Bio. The move is expected to position Artis among the first platforms in the United States to combine GMP synthetic DNA manufacturing with integrated advanced-therapy capabilities. Together, Artis, Landmark Bio, and Syngoi aim to broaden the range of solutions available to advanced-therapy developers in the U.S., Europe, and other global markets.
Syngoi’s GMP-ready facilities in Bilbao will become a central part of Artis’s global manufacturing footprint. Artis said it will continue investing in Syngoi’s operations and team in Bizkaia, in Spain’s Basque Country, with the site serving as a reference center supporting the company’s long-term vision in advanced therapies.
“This acquisition enables customers to reduce fragmentation and inefficiency in gene-to-drug development by introducing innovative synthetic DNA manufacturing solutions,” said Brian Neel, co-founder and chief executive officer of Artis BioSolutions. “By combining Syngoi Technologies and Landmark Bio, we expand our ability to support advanced-therapy programs from early development through clinical manufacturing, while continuing to invest in the teams and regions driving innovation.”
José Vicente Pons Andreu, chief executive officer of Syngoi, said the combination aligns closely with the company’s long-term goals. “Artis shares our long-term vision, and together with Landmark Bio, this partnership significantly enhances our ability to deliver differentiated synthetic DNA solutions at a global scale,” he said. “It strengthens our value proposition for customers and partners seeking reliable, high-quality platforms for advanced therapies.”
Julen Oyarzabal, co-founder and chief scientific officer of Syngoi, said the company has focused since its founding on developing a differentiated synthetic DNA platform capable of meeting the stringent requirements of advanced-therapy applications.
Investors also voiced support for the transaction. Andrew Adams, co-founder and managing partner at Oak HC/FT, said the acquisition strengthens Artis’s platform and expands the solutions available to its global customer base. Damia Tormo, managing partner at Columbus Venture Partners, said the deal positions Syngoi’s technology and team for long-term growth and impact within a strategic home.
The transaction is expected to close in the first quarter of 2026, subject to customary regulatory approvals and closing conditions. Financial terms were not disclosed.
